Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 6, 2012 - Issue 4
Submit an article Journal homepage
78
Views
13
CrossRef citations to date
0
Altmetric
Review

Current dilemmas in antimicrobial therapy in cystic fibrosis

Kamini Jain Division of Child Health, School of Clinical Sciences, University of Nottingham, E Floor, East Block, Queen’s Medical Centre, Derby Road, Nottingham, NG7 2UH, UK
&
Alan R Smyth Division of Child Health, School of Clinical Sciences, University of Nottingham, E Floor, East Block, Queen’s Medical Centre, Derby Road, Nottingham, NG7 2UH, UK. [email protected]
Pages 407-422 | Published online: 09 Jan 2014

References

  • Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur. Respir. J. 29(3), 522–526 (2007).
  • Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34(2), 91–100 (2002).
  • Gangell C, Gard S, Douglas T et al.; AREST CF. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin. Infect. Dis. 53(5), 425–432 (2011).
  • Stoltz DA, Meyerholz DK, Pezzulo AA et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl. Med. 2(29), 29ra31 (2010).
  • Armstrong DS, Hook SM, Jamsen KM et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmonol. 40(6), 500–510 (2005).
  • Goerke C, Wolz C. Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int. J. Med. Microbiol. 300(8), 520–525 (2010).
  • Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136(6), 1554–1560 (2009).
  • Elizur A, Orscheln RC, Ferkol TW et al. Panton–Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 131(6), 1718–1725 (2007).
  • UK Cystic Fibrosis Trust. UK Cystic Fibrosis Trust Antibiotic Working Group: Antibiotic Treatment for Cystic Fibrosis. UK Cystic Fibrosis Trust, London, UK (2009).
  • Flume PA, O’Sullivan BP, Robinson KA et al.; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957–969 (2007).
  • Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001912 (2003).
  • Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J. Pediatr. 140(3), 299–305 (2002).
  • Ratjen F, Comes G, Paul K, Posselt HG, Wagner TO, Harms K; German Board of the European Registry for Cystic Fibrosis (ERCF). Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr. Pulmonol. 31(1), 13–16 (2001).
  • Douglas TA, Brennan S, Gard S et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur. Respir. J. 33(2), 305–311 (2009).
  • Leahy TR, Yau YC, Atenafu E, Corey M, Ratjen F, Waters V. Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis. Pediatr. Pulmonol. 46(5), 489–496 (2011).
  • Sagel SD, Gibson RL, Emerson J et al.; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J. Pediatr. 154(2), 183–188 (2009).
  • Kosorok MR, Zeng L, West SE et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr. Pulmonol. 32(4), 277–287 (2001).
  • UK Cystic Fibrosis Trust. Pseudomonas aeruginosa Infection in People with Cystic Fibrosis: Report of the UK Cystic Fibrosis Trust Infection Control Group: Nov. 2004. UK Cystic Fibrosis Trust, London, UK (2004).
  • Saiman L, Siegel J; Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am. J. Infect. Control 31(3 Suppl.), S1–62 (2003).
  • Döring G. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. Int. J. Med. Microbiol. 300(8), 573–577 (2010).
  • Heinzl B, Eber E, Oberwaldner B, Haas G, Zach MS. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr. Pulmonol. 33(1), 32–37 (2002).
  • Tramper-Stranders GA, Wolfs TF, van Haren Noman S et al. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 65(10), 915–920 (2010).
  • Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 137(4), 861–868 (2010).
  • Lee TW. Eradication of early Pseudomonas infection in cystic fibrosis. Chron. Respir. Dis. 6(2), 99–107 (2009).
  • Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr. Respir. Rev. 11(3), 177–184 (2010).
  • Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 4, CD004197 (2009).
  • Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4), 286–291 (2010).
  • Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338(8769), 725–726 (1991).
  • Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 7(6), 523–530 (2008).
  • Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Respir. J. 26(3), 458–461 (2005).
  • Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23(5), 330–335 (1997).
  • Proesmans M, Boulanger L, Vermeulen F, DeBoeck K. Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ciprofloxacin. J. Cyst. Fibros. 7(Suppl. 2), S64 (2008).
  • Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N et al.; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 165(9), 847–856 (2011).
  • Noah TL, Ivins SS, Abode KA et al. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr. Pulmonol. 45(3), 281–290 (2010).
  • Munck A, Bonacorsi S, Mariani-Kurkdjian P et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr. Pulmonol. 32(4), 288–292 (2001).
  • Wainwright CE, Vidmar S, Armstrong DS et al.; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 306(2), 163–171 (2011).
  • Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J. Cyst. Fibros. 4(Suppl. 2), 49–54 (2005).
  • Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr. Pulmonol. 37(2), 104–110 (2004).
  • Gibson RL, Emerson J, Mayer-Hamblett N et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr. Pulmonol. 42(7), 610–623 (2007).
  • Goss CH, Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J. Cyst. Fibros. 10(5), 298–306 (2011).
  • Glikman D, Siegel JD, David MZ et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. aureus. Chest 133(6), 1381–1387 (2008).
  • Muhlebach MS, Popowitch E, Miller MB, Peng A, Lavange L, Saiman L. MRSA: epidemiology, molecular typing and antimicrobial susceptibilities: multicenter STAR-CF study. Pediatr. Pulmonol. 45(S33), 353 (2010).
  • Goodrich JS, Sutton-Shields TN, Kerr A, Wedd JP, Miller MB, Gilligan PH. Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. J. Clin. Microbiol. 47(4), 1231–1233 (2009).
  • Gillet Y, Issartel B, Vanhems P et al. Association between Staphylococcus aureus strains carrying gene for Panton–Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359(9308), 753–759 (2002).
  • Thomas SR, Gyi KM, Gaya H, Hodson ME. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J. Hosp. Infect. 40(3), 203–209 (1998).
  • Solís A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr. Pulmonol. 36(3), 189–195 (2003).
  • Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch. Dis. Child. 84(2), 160–162 (2001).
  • Muhlebach MS, Miller M, LaVange LM, Mayhew G, Goodrich JS, Miller MB. Treatment intensity and characteristics of MRSA infection in CF. J. Cyst. Fibros. 10(3), 201–206 (2011).
  • Ren CL, Morgan WJ, Konstan MW et al.; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr. Pulmonol. 42(6), 513–518 (2007).
  • Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(8), 814–821 (2008).
  • Sawicki GS, Rasouliyan L, Pasta DJ et al.; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 43(11), 1117–1123 (2008).
  • Nguyen T, Marcotte J, Bergeron C, Overchkine P, Denis M, Laberge S. Persistent MRSA in children with cystic fibrosis. Pediatr. Pulmonol. 45(S33), 354 (2010).
  • Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303(23), 2386–2392 (2010).
  • UK Cystic Fibrosis Trust Infection Control Working Group. Methicillin-Resistant Staphylococcus aureus (MRSA). UK Cystic Fibrosis Trust, London, UK (2008).
  • Máiz L, Cantón R, Mir N, Baquero F, Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr. Pulmonol. 26(4), 287–289 (1998).
  • Garske LA, Kidd TJ, Gan R et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J. Hosp. Infect. 56(3), 208–214 (2004).
  • Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr. Pulmonol. 33(3), 221–223 (2002).
  • Kappler M. Eradication of methicillin resistant Staphylococcus aureus in cystic fibrosis. J. Cyst. Fibros. 8(Suppl. 2), S42 (2009).
  • Serisier DJ, Jones G, Carroll M. Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J. Cyst. Fibros. 3(1), 61 (2004).
  • Macfarlane M, Leavy A, McCaughan J, Fair R, Reid AJ. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J. Hosp. Infect. 65(3), 231–236 (2007).
  • Doe SJ, McSorley A, Isalska B et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J. Cyst. Fibros. 9(2), 104–109 (2010).
  • Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340(7), 517–523 (1999).
  • Hill RL, Kearns AM, Nash J et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J. Antimicrob. Chemother. 65(3), 442–445 (2010).
  • UK Cystic Fibrosis Trust. The Burkholderia cepacia complex: Suggestions for Prevention and Infection Control, Report of the UK CF Trust Infection Control Group, Sep. 2004. UK Cystic Fibrosis Trust, London, UK (2004).
  • Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161(4 Pt 1), 1206–1212 (2000).
  • Etherington C, Peckham DG, Conway SP, Denton M. Burkholderia cepacia complex infection in adult patients with cystic fibrosis – is early eradication possible? J. Cyst. Fibros. 2(4), 220–221 (2003).
  • Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur. Respir. J. 26(2), 305–308 (2005).
  • Ball R, Brownlee KG, Duff AJ, Denton M, Conway SP, Lee TW. Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI? J. Cyst. Fibros. 9(1), 73–74 (2010).
  • UK Cystic Fibrosis Trust. UK Cystic Fibrosis Trust Annual Data Report 2010. UK Cystic Fibrosis Trust, London, UK (2010).
  • US CF Foundation. US CF Foundation Patient Registry 2010 Annual Data Report. US CF Foundation, MD, USA (2011).
  • Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23–30 (1999).
  • Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128(4), 2336–2346 (2005).
  • Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 20(3), 658–664 (2002).
  • Mowat E, Paterson S, Fothergill JL et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 183(12), 1674–1679 (2011).
  • Foweraker J. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br. Med. Bull. 89, 93–110 (2009).
  • Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19(6), 831–838 (1987).
  • McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178(9), 921–928 (2008).
  • Plosker GL. Aztreonam lysine for inhalation solution: in cystic fibrosis. Drugs 70(14), 1843–1855 (2010).
  • Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001021 (2003).
  • Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol. 21(3), 153–158 (1996).
  • Pedersen SS, Jensen T, Høiby N, Koch C, Flensborg EW. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr. Scand. 76(6), 955–961 (1987).
  • Brett MM, Simmonds EJ, Ghoneim AT, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch. Dis. Child. 67(9), 1086–1088 (1992).
  • Elborn JS, Prescott RJ, Stack BH et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 55(5), 355–358 (2000).
  • Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst. Rev. 4, CD002767 (2001).
  • Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case–control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 63(6), 532–535 (2008).
  • Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol. 39(1), 15–20 (2005).
  • Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 65(7), 654–658 (2010).
  • US CF Foundation. Microbiology and Infectious Disease in Cystic Fibrosis. US Cystic Fibrosis Foundation, MD, USA (1994).
  • Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123(5), 1495–1502 (2003).
  • Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 11(4), 288–292 (2012).
  • Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366(9484), 463–471 (2005).
  • Keays T, Ferris W, Vandemheen KL et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J. Cyst. Fibros. 8(2), 122–127 (2009).
  • Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur. J. Clin. Microbiol. Infect. Dis. 28(2), 191–195 (2009).
  • Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 15(5), 402–405 (1996).
  • Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121(6), 1754–1760 (2002).
  • Dalbøge CS, Hansen CR, Pressler T, Høiby N, Johansen HK. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J. Cyst. Fibros. 10(5), 318–325 (2011).
  • Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59(11), 955–959 (2004).
  • Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166(3), 356–361 (2002).
  • Waters V, Yau Y, Prasad S et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am. J. Respir. Crit. Care Med. 183(5), 635–640 (2011).
  • Waters V, Atenafu EG, Salazar JG et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J. Cyst. Fibros. 11(1), 8–13 (2012).
  • Cantón R, Valdezate S, Vindel A, Sánchez Del Saz B, Maíz L, Baquero F. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Pediatr. Pulmonol. 35(2), 99–107 (2003).
  • San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48(1), 168–171 (2004).
  • Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur. J. Clin. Microbiol. Infect. Dis. 26(4), 229–237 (2007).
  • Gülmez D, Cakar A, Sener B, Karakaya J, Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J. Infect. Chemother. 16(5), 322–328 (2010).
  • De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J. Cyst. Fibros. 6(1), 75–78 (2007).
  • Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J. Cyst. Fibros. 9(1), 51–58 (2010).
  • Lambiase A, Catania MR, Del Pezzo M et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 30(8), 973–980 (2011).
  • Rønne Hansen C, Pressler T, Høiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case–control study. J. Cyst. Fibros. 5(4), 245–251 (2006).
  • Saiman L, Chen Y, Tabibi S et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39(11), 3942–3945 (2001).
  • Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J. Clin. Microbiol. 43(7), 3467–3470 (2005).
  • Jordan PW, Stanley T, Donnelly FM et al. Atypical mycobacterial infection in patients with cystic fibrosis: update on clinical microbiology methods. Lett. Appl. Microbiol. 44(5), 459–466 (2007).
  • Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 641–645 (2000).
  • Aitken ML, Limaye A, Pottinger P et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am. J. Respir. Crit. Care Med. 185(2), 231–232 (2012).
  • Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J. Cyst. Fibros. 9(2), 117–123 (2010).
  • Griffith DE, Aksamit T, Brown-Elliott BA et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175(4), 367–416 (2007).
  • Olivier KN, Weber DJ, Lee JH et al.; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. II: Nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167(6), 835–840 (2003).
  • Jeon K, Kwon OJ, Lee NY et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am. J. Respir. Crit. Care Med. 180(9), 896–902 (2009).
  • Saleeb P, Olivier KN. Pulmonary nontuberculous mycobacterial disease: new insights into risk factors for susceptibility, epidemiology, and approaches to management in immunocompetent and immunocompromised patients. Curr. Infect. Dis. Rep. 12(3), 198–203 (2010).
  • Pihet M, Carrere J, Cimon B et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis – a review. Med. Mycol. 47(4), 387–397 (2009).
  • Stevens DA, Moss RB, Kurup VP et al.; Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin. Infect. Dis. 37(Suppl. 3), S225–S264 (2003).
  • Skov M, Høiby N, Koch C. Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Allergy 57(8), 723–728 (2002).
  • Elphick H, Southern K. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst. Rev. 4, CD002204 (2000).
  • Chaudhary N, Datta K, Askin FB, Staab JF, Marr KA. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am. J. Respir. Crit. Care Med. 185(3), 301–310 (2012).
  • Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin. Dev. Immunol. 2011, 843763 (2011).
  • Lebecque P, Leonard A, Argaz M, Godding V, Pilette C. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep. 2009, pii: bcr07.2008.0379 (2009).
  • Sibley CD, Grinwis ME, Field TR et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS ONE 6(7), e22702 (2011).
  • Delhaes L, Monchy S, Fréalle E et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community – implications for therapeutic management. PLoS ONE 7(4), e36313 (2012).
  • Parkins MD, Sibley CD, Surette MG, Rabin HR. The Streptococcus milleri group – an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr. Pulmonol. 43(5), 490–497 (2008).
  • Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence? Pediatr. Pulmonol. 40(6), 471–476 (2005).
  • Chatfield S, Owen G, Ryley HC et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch. Dis. Child. 66(1 Spec. No.), 29–33 (1991).
  • Weaver LT, Green MR, Nicholson K et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch. Dis. Child. 70(2), 84–89 (1994).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.